Patient Assistance

There are a number of financial assistance programs offered by Lung LLC to help your patients access ADCIRCA. To find the program that best meets their needs, contact ASSIST, your Access Solutions and Support Team.

To get a patient started with ASSIST, simply call the number above, or download the ASSIST form (English or Spanish version) by clicking on one of the icons at right, and complete and fax to 1-800-380-5294. Within 24 hours, an ASSIST Associate will follow up as preferred—with your practice or directly with your patient. Our ASSIST Associates are committed to resolving issues and managing cases until completion.

All patients can utilize the ASSIST program:

Patients with insurance
Patients with private/commercial insurance coverage may qualify for co-pay assistance with the ADCIRCA Co-pay Assistance Program. Click here to learn more. For patients with government health plans, or those who cannot access ADCIRCA due to issues with therapy authorization, there are other assistance programs that may be able to help. Please call ASSIST or fill out and fax the ASSIST form so we can explore your patients’ options.
Patients with no insurance
We may be able to help eligible patients obtain medication if they cannot afford it, are not adequately insured, or are close to the lifetime limit of their current insurance policy.*
Patients with interrupted coverage
We may be able to assist eligible patients in obtaining continued medication coverage, at a reasonable cost or no cost at all, if they experience a temporary interruption of therapy caused by a gap in insurance coverage.*

By calling 1-877-UNITHER (1-877-864-8437), our ASSIST Associates can also help with:

Benefit investigations
Confirmation of prior authorization documentation requirements
Denial/appeal assistance

ASSIST your patients with financial solutions and support.

*Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or federal or state programs, or patients in the state of Massachusetts, may not be eligible for some assistance. Some portion of this patient assistance may be administered by Caring Voice Coalition (CVC), an independent national nonprofit organization.

Important Safety Information

CONTRAINDICATIONS

Nitrates: ADCIRCA should not be used in patients taking medicines that contain nitrates, as the combination could cause a sudden, unsafe drop in blood pressure
Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA

WARNINGS AND PRECAUTIONS

Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention
Cardiovascular: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be adversely affected by such actions. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended
Cardiovascular: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
Potential Drug Interactions: Tadalafil is metabolized predominantly by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided
Special Populations: The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis^®, which is used to treat erectile dysfunction (ED). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended
Vision/Hearing: In rare instances, men taking PDE-5is (including tadalafil) for ED reported a sudden decrease or loss of vision or hearing, or an erection lasting more than four hours. A patient who experiences any of these symptoms should seek immediate medical attention

ADVERSE REACTIONS

Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)

For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.